PMID- 26399274
OWN - NLM
STAT- MEDLINE
DCOM- 20161221
LR  - 20220318
IS  - 1949-2553 (Electronic)
IS  - 1949-2553 (Linking)
VI  - 7
IP  - 7
DP  - 2016 Feb 16
TI  - Effectiveness and safety of poly (ADP-ribose) polymerase inhibitors in cancer 
      therapy: A systematic review and meta-analysis.
PG  - 7629-39
LID - 10.18632/oncotarget.5367 [doi]
AB  - Poly (ADP-ribose) polymerase (PARP) inhibitors are a class of small-molecule 
      drugs suppressing PARP enzymes activity, inducing the death of cells deficient in 
      homologous recombination repair (HRR). HRR deficiency is common in tumor cells 
      with BRCA gene mutation. Since their first clinical trial in 2003, PARP 
      inhibitors have shown benefit in the treatment of HRR-deficient tumors. Recently, 
      several randomized clinical trials (RCTs) have been conducted to investigate the 
      potential benefit of administration of PARP inhibitors in cancer patients. 
      However, the results remain controversial. To evaluate the efficiency and safety 
      of PARP inhibitors in patients with cancer, we performed a comprehensive 
      meta-analysis of RCTs. According to our study, PARP inhibitors could clearly 
      improve progression-free survival (PFS), especially in patients with BRCA 
      mutation. However, our study showed no significant difference in overall survival 
      (OS) between the PARP inhibitors and controls, even in the BRCA mutation group. 
      Little toxicity was reported in the rate of treatment correlated adverse events 
      (AEs) in PARP inhibitor group compared with controls. In conclusion, PARP 
      inhibitors do well in improving PFS with little toxicity, especially in patients 
      with BRCA deficiency.
FAU - Bao, Zhengqiang
AU  - Bao Z
AD  - Department of Respiratory and Critical Care Medicine, Second Affiliated Hospital, 
      Institute of Respiratory Diseases, Zhejiang University School of Medicine, 
      Hangzhou, China.
AD  - Department of Pharmacology, Zhejiang University School of Medicine, Hangzhou, 
      China.
FAU - Cao, Chao
AU  - Cao C
AD  - Department of Respiratory and Critical Care Medicine, Second Affiliated Hospital, 
      Institute of Respiratory Diseases, Zhejiang University School of Medicine, 
      Hangzhou, China.
FAU - Geng, Xinwei
AU  - Geng X
AD  - Department of Pharmacology, Zhejiang University School of Medicine, Hangzhou, 
      China.
FAU - Tian, Baoping
AU  - Tian B
AD  - Department of Respiratory and Critical Care Medicine, Second Affiliated Hospital, 
      Institute of Respiratory Diseases, Zhejiang University School of Medicine, 
      Hangzhou, China.
FAU - Wu, Yanping
AU  - Wu Y
AD  - Department of Respiratory and Critical Care Medicine, Second Affiliated Hospital, 
      Institute of Respiratory Diseases, Zhejiang University School of Medicine, 
      Hangzhou, China.
FAU - Zhang, Chao
AU  - Zhang C
AD  - Department of Respiratory and Critical Care Medicine, Second Affiliated Hospital, 
      Institute of Respiratory Diseases, Zhejiang University School of Medicine, 
      Hangzhou, China.
FAU - Chen, Zhihua
AU  - Chen Z
AD  - Department of Respiratory and Critical Care Medicine, Second Affiliated Hospital, 
      Institute of Respiratory Diseases, Zhejiang University School of Medicine, 
      Hangzhou, China.
FAU - Li, Wen
AU  - Li W
AD  - Department of Respiratory and Critical Care Medicine, Second Affiliated Hospital, 
      Institute of Respiratory Diseases, Zhejiang University School of Medicine, 
      Hangzhou, China.
FAU - Shen, Huahao
AU  - Shen H
AD  - Department of Respiratory and Critical Care Medicine, Second Affiliated Hospital, 
      Institute of Respiratory Diseases, Zhejiang University School of Medicine, 
      Hangzhou, China.
AD  - State Key Laboratory for Respiratory Diseases, Guangzhou, China.
FAU - Ying, Songmin
AU  - Ying S
AD  - Department of Respiratory and Critical Care Medicine, Second Affiliated Hospital, 
      Institute of Respiratory Diseases, Zhejiang University School of Medicine, 
      Hangzhou, China.
AD  - Department of Pharmacology, Zhejiang University School of Medicine, Hangzhou, 
      China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PT  - Systematic Review
PL  - United States
TA  - Oncotarget
JT  - Oncotarget
JID - 101532965
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Poly(ADP-ribose) Polymerase Inhibitors)
RN  - EC 2.4.2.30 (Poly(ADP-ribose) Polymerases)
SB  - IM
MH  - Antineoplastic Agents/*therapeutic use
MH  - Humans
MH  - Neoplasms/*drug therapy
MH  - Poly(ADP-ribose) Polymerase Inhibitors/*therapeutic use
MH  - Poly(ADP-ribose) Polymerases/*chemistry
MH  - Safety
PMC - PMC4884943
OTO - NOTNLM
OT  - BRCA
OT  - Olaparib
OT  - PARP
OT  - cancer
OT  - clinical trials
OT  - synthetic lethality
COIS- CONFLICTS OF INTEREST None.
EDAT- 2015/09/25 06:00
MHDA- 2016/12/22 06:00
PMCR- 2016/02/16
CRDT- 2015/09/25 06:00
PHST- 2015/06/22 00:00 [received]
PHST- 2015/09/11 00:00 [accepted]
PHST- 2015/09/25 06:00 [entrez]
PHST- 2015/09/25 06:00 [pubmed]
PHST- 2016/12/22 06:00 [medline]
PHST- 2016/02/16 00:00 [pmc-release]
AID - 5367 [pii]
AID - 10.18632/oncotarget.5367 [doi]
PST - ppublish
SO  - Oncotarget. 2016 Feb 16;7(7):7629-39. doi: 10.18632/oncotarget.5367.